| abstract |
A pharmaceutical composition comprising in a unit dose formulation 3- [5- (2- fluorophenyl) - [1,2,4] oxadiazol-3-yl] -benzoic acid or a pharmaceutically acceptable solvate or hydrate salt thereof in an amount of between 35 mg and 1400 mg, refined polydextrose, poloxamer powder 407, polyethylene glycol 3350, mannitol, crospovidone, and one or more excipients selected from hydroxyethyl cellulose, vanilla flavor, non-bovine magnesium stearate and colloidal silica. |